Merck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus®
Dateline City:
KENILWORTH, N.J.
Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced results from two Phase 3 studies evaluating MK-1293,
Merck’s investigational, follow-on biologic* insulin glargine candidate
for the treatment of people with type 1 and type 2 diabetes.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Kristen Drake, 908-334-4688orInvestor:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK MSD Source Type: news
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Endocrinology | Insulin | Lantus | Merck | Pharmaceuticals | Study